Jasper Therapeutics, Inc.
JSPR
$2.92
-$0.04-1.35%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -45.62% | -23.23% | -10.55% | -3.98% | -12.67% |
| Total Depreciation and Amortization | 15.45% | 21.57% | 23.92% | 28.51% | 5.14% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 57.70% | 64.04% | 14.77% | -2.75% | -1.89% |
| Change in Net Operating Assets | 6,481.36% | -119.10% | -96.22% | -138.49% | -96.11% |
| Cash from Operations | -31.51% | -21.30% | -20.23% | -20.14% | -21.74% |
| Capital Expenditure | 8.50% | -98.12% | -106.74% | -476.47% | -20.82% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 16.26% | -89.10% | -99.25% | -476.47% | -20.82% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -86.31% | -98.88% | -53.02% | -53.33% | -53.29% |
| Repurchase of Common Stock | -- | -- | -- | 54.77% | 54.77% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -86.22% | -98.86% | -52.58% | -53.32% | -53.28% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -648.46% | -537.77% | -131.35% | -121.48% | -116.35% |